Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Clopidogrel is a widely used antiplatelet medication crucial for preventing thrombotic events in cardiology patients.
• Assessing patient response to clopidogrel is vital for optimizing treatment efficacy and preventing adverse cardiovascular events.

Purpose of the Study:

• To evaluate platelet function before and after clopidogrel therapy in cardiology candidates undergoing intervention.
• To identify potential predictors of clopidogrel nonresponse.

Main Methods:

• Optical platelet aggregation was used to measure platelet function.
• Two point-of-care instruments, Thrombelastograph and Ichor PlateletWorks, were employed and showed significant correlation.
• Platelet function was assessed in 50 cardiology patients before and after initiating clopidogrel treatment.

Main Results:

• A significant proportion of patients (30%) were identified as nonresponders to clopidogrel therapy, defined as less than 10% average platelet inhibition.
• No correlation was found between clopidogrel nonresponse and clinical pretreatment variables such as atorvastatin therapy.
• The study observed no association between clopidogrel nonresponse and postintervention bleeding complications or major adverse coronary events in this cohort.

Conclusions:

• A notable percentage of cardiology patients exhibit nonresponse to standard clopidogrel therapy.
• Pretreatment clinical variables, including atorvastatin use, do not reliably predict clopidogrel nonresponse.
• Further research is warranted to elucidate the mechanisms behind clopidogrel nonresponse and its clinical implications for cardiovascular outcomes.